SAN FRANCISCO, CA–(Feb 19, 2014) – Amarantus Bioscience Holdings, Inc. (OTCBB: AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that Gerald Commissiong, President and CEO will be interviewed live today by host Michael Yorba on Clear Channel Business Talk Radio’s The Traders Network.

 

All investors, analysts, industry professionals and prospective customers that are interested to learn more about Amarantus Bioscience, its goals and recent developments are invited to tune in and listen live via Clear Channel’s nationally syndicated iHeart Radio stream.

 

The interview will air today, Tuesday, February 18, 2014 at 1:05pm U.S. CST / 11:05am PST / 2:05pm EST on Clear Channel DFW 1190AM.

 

Live iHeart Radio Stream: http://www.iheart.com/live/4276/?autoplay=true
Time: 1:05pm CST | 11:05pm PST | 2:05pm EST (U.S.)
Date: February 19, 2014
Network: Clear Channel
Station: DFW 1190 AM KFXR
Host: Michael Yorba

 

About Clear Channel: Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. www.clearchannel.com.

 

About Michael Yorba: Mr. Yorba is the founder of Yorba Media and featured host on Clear Channel. For the past six years he has been integrally involved with producing and hosting a daily talk show called Commodity Classics, and The Traders Network.

 

From the fast action of the trading pit… to the power brokers making the headlines… Michael Yorba interviews the front-page Titans about the latest in capital markets, CEO milestones, trading tools, real estate acquisitions and market trends. Learn how the experts use risk management techniques to build fully diversified portfolios and what it takes to put up big board earnings. It’s a fast moving, high-energy show that presents stocks, commodities, bonds, forex, derivatives, real estate, political trends, technology trends, crowd funding and impact investment insights in a new light and keeps investors and consumers asking for more… The Traders Network stays ahead of the curve by featuring leading market and business professionals, sophisticated technology, and the analytics needed to identify the most lucrative investment strategies. Successful performance depends on finding the right opportunities. So… shift your thinking and join us as we deliver “tomorrow’s ideas today” on Clear Channel’s the Traders Network Monday – Friday from 1:00pm – 3:00pm CST live after Glenn Beck.

 

About Amarantus: Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. The Company has licensed Eltoprazine a phase 2b ready indication for Parkinson’s Levodopa induced dyskinesia and Adult ADHD The Company has an exclusive worldwide license to the Lymphocyte Proliferation test (“LymPro Test®”) for Alzheimer’s disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (“MANF”) and is developing MANF-based products as treatments for brain disorders. Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson’s disease (“NuroPro”) and the discovery of neurotrophic factors (“PhenoGuard”). For further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.

 

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements.” These forward-looking statements generally are identified by the words believes,” project,” expects,” anticipates,” estimates,” intends,” strategy,” plan,” may,” will,” would,” will be,” will continue,” will likely result,” and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include but are not limited to changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

 

A CommPro Worldwide PR Event

 

Contacts:

 

PR & Media Contact:

Matt Bird, CEO
CommPro Worldwide

C: +1 (646) 401-4499
E: matt.bird@commpro.com

 

For more information visit: commpro.com | Twitter | LinkedIn | Facebook